191 related articles for article (PubMed ID: 17404098)
1. Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity.
Hussain SR; Cheney CM; Johnson AJ; Lin TS; Grever MR; Caligiuri MA; Lucas DM; Byrd JC
Clin Cancer Res; 2007 Apr; 13(7):2144-50. PubMed ID: 17404098
[TBL] [Abstract][Full Text] [Related]
2. Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance.
Bannerji R; Kitada S; Flinn IW; Pearson M; Young D; Reed JC; Byrd JC
J Clin Oncol; 2003 Apr; 21(8):1466-71. PubMed ID: 12697868
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation.
Kang MH; Wan Z; Kang YH; Sposto R; Reynolds CP
J Natl Cancer Inst; 2008 Apr; 100(8):580-95. PubMed ID: 18398104
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis.
Alas S; Emmanouilides C; Bonavida B
Clin Cancer Res; 2001 Mar; 7(3):709-23. PubMed ID: 11297268
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of mcl-1 by small interfering RNA sensitizes resistant melanoma cells to fas-mediated apoptosis.
Chetoui N; Sylla K; Gagnon-Houde JV; Alcaide-Loridan C; Charron D; Al-Daccak R; Aoudjit F
Mol Cancer Res; 2008 Jan; 6(1):42-52. PubMed ID: 18234961
[TBL] [Abstract][Full Text] [Related]
6. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels.
Czuczman MS; Olejniczak S; Gowda A; Kotowski A; Binder A; Kaur H; Knight J; Starostik P; Deans J; Hernandez-Ilizaliturri FJ
Clin Cancer Res; 2008 Mar; 14(5):1561-70. PubMed ID: 18316581
[TBL] [Abstract][Full Text] [Related]
7. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1.
Gojo I; Zhang B; Fenton RG
Clin Cancer Res; 2002 Nov; 8(11):3527-38. PubMed ID: 12429644
[TBL] [Abstract][Full Text] [Related]
8. Rituximab and 17-allylamino-17-demethoxygeldanamycin induce synergistic apoptosis in B-cell chronic lymphocytic leukaemia.
Johnson AJ; Wagner AJ; Cheney CM; Smith LL; Lucas DM; Guster SK; Grever MR; Lin TS; Byrd JC
Br J Haematol; 2007 Dec; 139(5):837-44. PubMed ID: 17949452
[TBL] [Abstract][Full Text] [Related]
9. Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression.
Olejniczak SH; Hernandez-Ilizaliturri FJ; Clements JL; Czuczman MS
Clin Cancer Res; 2008 Mar; 14(5):1550-60. PubMed ID: 18316580
[TBL] [Abstract][Full Text] [Related]
10. Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum.
Lefebvre ML; Krause SW; Salcedo M; Nardin A
J Immunother; 2006; 29(4):388-97. PubMed ID: 16799334
[TBL] [Abstract][Full Text] [Related]
11. The three-substituted indolinone cyclin-dependent kinase 2 inhibitor 3-[1-(3H-imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one (SU9516) kills human leukemia cells via down-regulation of Mcl-1 through a transcriptional mechanism.
Gao N; Kramer L; Rahmani M; Dent P; Grant S
Mol Pharmacol; 2006 Aug; 70(2):645-55. PubMed ID: 16672643
[TBL] [Abstract][Full Text] [Related]
12. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy.
Jazirehi AR; Vega MI; Bonavida B
Cancer Res; 2007 Feb; 67(3):1270-81. PubMed ID: 17283164
[TBL] [Abstract][Full Text] [Related]
13. VSV virotherapy improves chemotherapy by triggering apoptosis due to proteasomal degradation of Mcl-1.
Schache P; Gürlevik E; Strüver N; Woller N; Malek N; Zender L; Manns M; Wirth T; Kühnel F; Kubicka S
Gene Ther; 2009 Jul; 16(7):849-61. PubMed ID: 19369968
[TBL] [Abstract][Full Text] [Related]
14. A pivotal role for Mcl-1 in Bortezomib-induced apoptosis.
Podar K; Gouill SL; Zhang J; Opferman JT; Zorn E; Tai YT; Hideshima T; Amiot M; Chauhan D; Harousseau JL; Anderson KC
Oncogene; 2008 Jan; 27(6):721-31. PubMed ID: 17653083
[TBL] [Abstract][Full Text] [Related]
15. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
Wu L; Adams M; Carter T; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB
Clin Cancer Res; 2008 Jul; 14(14):4650-7. PubMed ID: 18628480
[TBL] [Abstract][Full Text] [Related]
16. Mcl-1 is a novel therapeutic target for human sarcoma: synergistic inhibition of human sarcoma xenotransplants by a combination of mcl-1 antisense oligonucleotides with low-dose cyclophosphamide.
Thallinger C; Wolschek MF; Maierhofer H; Skvara H; Pehamberger H; Monia BP; Jansen B; Wacheck V; Selzer E
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4185-91. PubMed ID: 15217956
[TBL] [Abstract][Full Text] [Related]
17. Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction.
Schulze-Bergkamen H; Fleischer B; Schuchmann M; Weber A; Weinmann A; Krammer PH; Galle PR
BMC Cancer; 2006 Oct; 6():232. PubMed ID: 17014711
[TBL] [Abstract][Full Text] [Related]
18. [Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells].
Shi YX; Zhang XS; Xia JC; Li YQ; Xu RH; Han WJ; Zhang JH; Guan ZZ; Jiang WQ
Ai Zheng; 2007 Aug; 26(8):837-42. PubMed ID: 17697543
[TBL] [Abstract][Full Text] [Related]
19. T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro.
Gall JM; Davol PA; Grabert RC; Deaver M; Lum LG
Exp Hematol; 2005 Apr; 33(4):452-9. PubMed ID: 15781336
[TBL] [Abstract][Full Text] [Related]
20. Improvement of rituximab efficiency in chronic lymphocytic leukemia by CpG-mediated upregulation of CD20 expression independently of PU.1.
Mankaï A; Buhé V; Hammadi M; Youinou P; Ghedira I; Berthou C; Bordron A
Ann N Y Acad Sci; 2009 Sep; 1173():721-8. PubMed ID: 19758221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
